Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
复制标题
DOI：
10.1016/j.surneu.2006.08.080
复制
发表时间：
2007-04-01
影响因子：
--
通讯作者：
Sotelo, Julio
中科院分区：
文献类型：
--
作者：
Briceno, Eduardo;Calderon, Alejandra;Sotelo, Julio
背景：目前治疗GBM的结果令人沮丧；患者的平均生存时间约为1年，几十年来一直如此。在初步研究中，我们观察到在GBM的常规治疗中加入氯喹可以增强治疗效果。方法：在过去的5年中，41例GBM患者在常规手术、化疗和放疗的同时接受了氯喹作为可选的辅助治疗。这些患者没有参加我们之前关于氯喹给药的研究，并进行回顾性研究；本分析纳入82例未接受氯喹治疗的当代GBM患者作为对照。观察终点为术后生存时间。结果：氯喹组患者生存时间为25 +/- 3.4个月，对照组为11.4 +/- 1.3个月（P = 0.000; OR = 0.4; 95% Cl = 0.26-0.6）；在对可能的临床混杂因素进行回归分析后，差异仍然显著。结论：与我们最近的报道一致，氯喹在GBM的常规治疗中有很强的辅助作用。在这个未经选择的GBM患者的大队列中，接受氯喹治疗的中位生存时间是对照组的两倍。(c) 2007爱思唯尔公司版权所有。
Background: Results of the current therapy for GBM are dismal; the mean survival time of patients is approximately I year-and it has been so for several decades. In preliminary studies, we have observed a potentiating therapeutic effect when cbloroquine was added to the conventional treatment of GBM.Methods: Over the last 5 years, 41 patients with GBM received chloroquine as an optional adjuvant administered concurrently with conventional surgery, chemotherapy, and radiotherapy. These patients did not participate in our previous studies on chloroquine administration and were studied retrospectively; 82 contemporary patients with GBM who did not receive chloroquine were included in this analysis as control subjects. The end point observed was time of survival after surgery.Results: Survival time in patients treated with chloroquine was 25 +/- 3.4 months, as compared with that of 11.4 +/- 1.3 months in control subjects (P = .000; OR = 0.4; 95% Cl = 0.26-0.6); the difference remained significant after regression analysis for possible clinical confounders.Conclusions: In agreement with our recent reports, chloroquine exerts a strong adjuvant effect when added to the conventional treatment of GBM. In this large cohort of unselected patients with GBM who were treated with chloroquine, the median survival time doubled as compared with that of control subjects. (c) 2007 Elsevier Inc. All rights reserved.